Publications

  1. Zahrieh D, Kandler BW, Le-Rademacher J. The symbolic two-step method applied to cancer care delivery research: Safeguarding against designing an underpowered cluster randomized trial with a continuous outcome by accounting for the imprecision in the within- and between-center variation. Clin Trials. 2024 Aug; 21 (4):430-439 Epub 2024 Jan 19
    View PubMed
  2. Leon-Ferre RA, Carter JM, Zahrieh D, Sinnwell JP, Salgado R, Suman VJ, Hillman DW, Boughey JC, Kalari KR, Couch FJ, Ingle JN, Balkenhol M, Ciompi F, van der Laak J, Goetz MP. Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer. NPJ Breast Cancer. 2024 Mar 29; 10 (1):25
    View PubMed
  3. Smith EML, Cho Y, Hillman S, Scott MR, Harlos E, Wills R, Loprinzi C, Wilson CM, Zahrieh D. Patient-targeted education (ePRO-E) to increase ePRO intent within an Alliance clinical trial (A221805-SI1). JNCI Cancer Spectr. 2024 Jan 4; 8 (1)
    View PubMed
  4. Tanabe KK, Zahrieh D, Strand CA, Hoshida Y, Flotte TJ, Della'Zanna G, Umar A, Chavin KD, Cleary S, Kubota N, Llovet JM, Patel T, Siegel C, Limburg PJ. Epidermal Growth Factor Receptor Inhibition With Erlotinib in Liver: Dose De-Escalation Pilot Trial as an Initial Step in a Chemoprevention Strategy. Gastro Hep Adv. 2024; 3 (3):426-439 Epub 2024 Jan 29
    View PubMed
  5. Zahrieh D, Croghan IT, Inselman JW, Mandrekar SJ. Guidelines for Data and Safety Monitoring in Pragmatic Randomized Clinical Trials Using Case Studies. Mayo Clin Proc. 2023 Nov; 98 (11):1712-1726
    View PubMed
  6. Ivory J, Wheeler SB, Drier S, Gunn H, Zahrieh D, Paskett E, Naughton M, Wills R, Swetel K, Chow S, Reeder-Hayes K. Randomized phase III trial evaluating motivational interviewing and text interventions to optimize adherence to breast cancer endocrine therapy (Alliance A191901): the GETSET protocol. Trials. 2023 Oct 12; 24 (1):664
    View PubMed
  7. Cho Y, Lavoie Smith EM, Zahrieh D, Chow SL, Williams DA, Saint Arnault D, Jiang Y. Electronic Patient-Reported Outcome Data Collection Systems in Oncology Clinical Trials: A Survey of Clinical Research Professionals (an Alliance Study). JCO Clin Cancer Inform. 2023 Sep; 7:e2300007
    View PubMed
  8. Schoen RE, Boardman LA, Cruz-Correa M, Bansal A, Kastenberg D, Hur C, Dzubinski L, Kaufman SF, Rodriguez LM, Richmond E, Umar A, Szabo E, Salazar A, McKolanis J, Beatty P, Pai RK, Singhi AD, Jacqueline CM, Bao R, Diergaarde B, McMurray RP, Strand C, Foster NR, Zahrieh DM, Limburg PJ, Finn OJ. Randomized, Double-Blind, Placebo-Controlled Trial of MUC1 Peptide Vaccine for Prevention of Recurrent Colorectal Adenoma. Clin Cancer Res. 2023 May 1; 29 (9):1678-1688
    View PubMed
  9. Joyce DD, Tilburt JC, Pacyna JE, Cina K, Petereit DG, Koller KR, Flanagan CA, Stillwater B, Miller M, Kaur JS, Peil E, Zahrieh D, Dueck AC, Montori VM, Frosch DL, Volk RJ, Kim SP. The Impact of Within-Consultation and Preconsultation Decision Aids for Localized Prostate Cancer on Patient Knowledge: Results of a Patient-Level Randomized Trial. Urology. 2023 May; 175:90-95 Epub 2023 Mar 09
    View PubMed
  10. Carter JM, Chumsri S, Hinerfeld DA, Ma Y, Wang X, Zahrieh D, Hillman DW, Tenner KS, Kachergus JM, Brauer HA, Warren SE, Henderson D, Shi J, Liu Y, Joensuu H, Lindman H, Leon-Ferre RA, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Knutson KL, Goetz MP, Perez EA, Thompson EA. Distinct spatial immune microlandscapes are independently associated with outcomes in triple-negative breast cancer. Nat Commun. 2023 Apr 18; 14 (1):2215
    View PubMed
  11. Cathcart-Rake EJ, Zahrieh D, Smith D, Young S, McCue S, O'Connor A, Thome S, Lacouture M, Register T, Piens J, Friday BB, Loprinzi CL. A five arm natural history study of nasal vestibulitis. Cancer Med. 2023 Apr; 12 (8):9650-9654 Epub 2023 Apr 05
    View PubMed
  12. Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, Barranco E, Richmond E, Umar A, Weiner DB, Limburg PJ, Cancer Prevention Network. Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prev Res (Phila). 2023 Mar 1; 16 (3):163-173
    View PubMed
  13. Samadder NJ, Foster N, McMurray RP, Burke CA, Stoffel E, Kanth P, Das R, Cruz-Correa M, Vilar E, Mankaney G, Buttar N, Thirumurthi S, Turgeon DK, Sossenheimer M, Westover M, Richmond E, Umar A, Della'Zanna G, Rodriguez LM, Szabo E, Zahrieh D, Limburg PJ. Phase II trial of weekly erlotinib dosing to reduce duodenal polyp burden associated with familial adenomatous polyposis. Gut. 2023 Feb; 72 (2):256-263 Epub 2022 May 30
    View PubMed
  14. Ruddy KJ, Zahrieh D, He J, Waechter B, Holleran JL, Lewis LD, Chow S, Beumer J, Weiss M, Trikalinos N, Faller B, Lustberg M, Rugo HS, Loprinzi C. Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Semin Oncol. 2023 Feb-Apr; 50 (1-2):7-10 Epub 2023 Jan 17
    View PubMed
  15. Roesler AS, Malasi S, Koslosky L, Hartmayer P, Naab TJ, Carter JM, Zahrieh D, Hillman D, Leon-Ferre RA, Couch FJ, Goetz MP, Anderson KS, Pockaj BA, Barrett MT. PDJ amplicon in triple negative breast cancer. Sci Rep. 2023 Jan 12; 13 (1):618
    View PubMed
  16. Hawley ST, Kidwell K, Zahrieh D, McCarthy A, Wills R, Rankin A, Hofer T, Chow S, Jagsi R, Neuman H. Improving patient-centered communication in breast cancer: a study protocol for a multilevel intervention of a shared treatment deliberation system (SharES) within the NCI community oncology research program (NCORP) (Alliance A231901CD). Trials. 2023 Jan 6; 24 (1):16 Epub 2023 Jan 06
    View PubMed
  17. Jacobson JM, Zahrieh D, Strand CA, Cruz-Correa M, Pungpapong S, Roberts LR, Mandrekar SJ, Rodriguez LM, Boyer J, Marrero I, Kraynyak KA, Morrow MP, Sylvester AJ, Pawlicki JM, Gillespie E, Barranco E, Richmond E, Umar A, Weiner DB, Limburg PJ. Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prev Res (Phila). 2022 Dec 7 Epub 2022 Dec 07
    View PubMed
  18. Schumacher JR, Zahrieh D, Chow S, Taylor J, Wills R, Hanlon BM, Rathouz PJ, Tucholka JL, Neuman HB. Increasing socioeconomically disadvantaged patients' engagement in breast cancer surgery decision-making through a shared decision-making intervention (A231701CD): protocol for a cluster randomised clinical trial. BMJ Open. 2022 Nov 17; 12 (11):e063895
    View PubMed
  19. Kellogg Parsons J, Zahrieh D, Patel D, Mohler JL, Chen RC, Paskett ED, Liu H, Peil ES, Rock CL, Hahn O, Taylor J, Van Veldhuizen PJ Jr, Small EJ, Morris MJ, Naughton MJ, Pierce JP, Marshall J. Diet and Health-related Quality of Life Among Men on Active Surveillance for Early-stage Prostate Cancer: The Men's Eating and Living Study (Cancer and Leukemia Group 70807 [Alliance]). Eur Urol Focus. 2022 Nov; 8 (6):1607-1616 Epub 2022 Apr 30
    View PubMed
  20. Zahrieh D, Hillman SL, Tan AD, Frank JL, Dockter T, Meyers BJ, Cherevko CL, Peil ES, McCue S, Kour O, Gunn HJ, Neuman HB, Chang GJ, Paskett ED, Mandrekar SJ, Dueck AC. Successes and lessons learned in database development for national multi-site cancer care delivery research trials: the Alliance for Clinical Trials in Oncology experience. Trials. 2022 Aug 09; 23(1):645.
    View PubMed
  21. Thompson KJ, Leon-Ferre RA, Sinnwell JP, Zahrieh DM, Suman VJ, Metzger FO, Asad S, Stover DG, Carey L, Sikov WM, Ingle JN, Liu MC, Carter JM, Klee EW, Weinshilboum RM, Boughey JC, Wang L, Couch FJ, Goetz MP, Kalari KR. Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response. NAR Cancer. 2022 Jun; 4 (2):zcac018 Epub 2022 June 17
    View PubMed
  22. Kehl KL, Zahrieh D, Yang P, Hillman SL, Tan AD, Sands JM, Oxnard GR, Gillaspie EA, Wigle D, Malik S, Stinchcombe TE, Ramalingam SS, Kelly K, Govindan R, Mandrekar SJ, Osarogiagbon RU, Kozono D. Rates of Guideline-Concordant Surgery and Adjuvant Chemotherapy Among Patients With Early-Stage Lung Cancer in the US ALCHEMIST Study (Alliance A151216). JAMA Oncol. 2022 May 1; 8 (5):717-728
    View PubMed
  23. Tilburt JC, Zahrieh D, Pacyna JE, Petereit DG, Kaur JS, Rapkin BD, Grubb RL 3rd, Chang GJ, Morris MJ, Kovac EZ, Babaian KN, Sloan JA, Basch EM, Peil ES, Dueck AC, Novotny PJ, Paskett ED, Buckner JC, Joyce DD, Montori VM, Frosch DL, Volk RJ, Kim SP. Decision aids for localized prostate cancer in diverse minority men: Primary outcome results from a multicenter cancer care delivery trial (Alliance A191402CD). Cancer. 2022 Mar 15; 128 (6):1242-1251 Epub 2021 Dec 10
    View PubMed
  24. Zahrieh D, Kandler BW, Le-Rademacher J. Symbolic two-step method compared with single-step methods to model the center-mean outcome in cluster randomized trials. Contemp Clin Trials. 2022 Mar; 114:106684 Epub 2022 Jan 18
    View PubMed
  25. Zahrieh D, Satele D, Smith EML, Loprinzi CL, Le-Rademacher J. Temporal, Location- and Symptom-Specific Likelihood of Patient-Reported Sensory Symptoms Related to Oxaliplatin-Induced Peripheral Neuropathy (OIPN) in Patients Receiving Oxaliplatin for Three Months. Cancers (Basel). 2022 Feb 25; 14 (5)
    View PubMed
  26. He J, Perez DG, Le-Rademacher JL, Dodge A, Enck P, Loprinzi CL, Zahrieh D. Does the placebo effect on hot flashes depend on the placebo dose? Support Care Cancer. 2021 Nov; 29 (11):6741-6749 Epub 2021 May 11
    View PubMed
  27. Cathcart-Rake EJ, Zahrieh D, Smith D, Young S, McCue S, O'Connor A, Thome S, Lacouture M, Register T, Piens J, Friday BB, Loprinzi CL. Natural history of nasal vestibulitis associated with paclitaxel, docetaxel, and other chemotherapy agents: a Minnesota Cancer Clinical Trials Network (MNCCTN) study. Support Care Cancer. 2021 Nov; 29 (11):6253-6258 Epub 2021 Apr 13
    View PubMed
  28. Carter JM, Polley MC, Leon-Ferre RA, Sinnwell J, Thompson KJ, Wang X, Ma Y, Zahrieh D, Kachergus JM, Solanki M, Boughey JC, Liu MC, Ingle JN, Kalari KR, Couch FJ, Thompson EA, Goetz MP. Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer. Clin Cancer Res. 2021 Oct 15; 27(20):5628-5637. Epub 2021 Jun 09.
    View PubMed
  29. Wood ME, Liu H, Storrick E, Zahrieh D, Le-Petross HC, Jung SH, Zekan P, Kemeny MM, Charlamb JR, Wang LX, Unzeitig GW, Johnson CS, Garber JE, Marshall JR, Bedrosian I. The Influence of Vitamin D on Mammographic Density: Results from CALGB 70806 (Alliance) a Randomized Clinical Trial. Cancer Prev Res (Phila). 2021 Jul; 14 (7):753-762 Epub 2021 Apr 13
    View PubMed
  30. Maggiore RJ, Zahrieh D, McMurray RP, Feliciano JL, Samson P, Mohindra P, Chen H, Wong ML, Lafky JM, Jatoi A, Le-Rademacher JG. Toxicity and survival outcomes in older adults receiving concurrent or sequential chemoradiation for stage III non-small cell lung cancer in Alliance trials (Alliance A151812). J Geriatr Oncol. 2021 May; 12 (4):563-571 Epub 2020 Sept 16
    View PubMed
  31. Zahrieh D, Golafshar MA, Patel SH, DeWees TA. Quantification of Potential Inequities in Breast Cancer Incidence in New Mexico Through Bayesian Disease Mapping. Prev Chronic Dis. 2021 Mar 11; 18:E23
    View PubMed
  32. Cathcart-Rake EJ, Smith D, Zahrieh D, Loprinzi CL. Rose geranium in sesame oil nasal spray: a treatment for nasal vestibulitis? BMJ Support Palliat Care. 2020 Dec; 10 (4):411-413 Epub 2018 Sept 26
    View PubMed
  33. Zayas J, Ruddy KJ, Olson JE, Couch FJ, Bauer BA, Mallory MJ, Yang P, Zahrieh D, Athreya AP, Loprinzi CL, Cathcart-Rake EJ. Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study. Support Care Cancer. 2020 Dec; 28 (12):5833-5838 Epub 2020 Apr 06
    View PubMed
  34. Zahrieh D, Le-Rademacher J. Sample size planning in the design and analysis of cluster randomized trials using the symbolic two-step method. Contemp Clin Trials Commun. 2020 Sep; 19:100609 Epub 2020 July 08
    View PubMed
  35. Patel AA, Wheeler PH, Wi CI, Derauf C, Ryu E, Zahrieh D, Bjur KA, Juhn YJ. Mobile home residence as a risk factor for adverse events among children in a mixed rural-urban community: A case for geospatial analysis. J Clin Transl Sci. 2020 Apr 6; 4 (5):443-450 Epub 2020 Apr 06
    View PubMed
  36. Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, Liu H, Seisler DK, Natarajan L, White M, Hahn O, Taylor J, Hartman SJ, Stroup SP, Van Veldhuizen P, Hall L, Small EJ, Morris MJ, Pierce JP, Marshall J. Effect of a Behavioral Intervention to Increase Vegetable Consumption on Cancer Progression Among Men With Early-Stage Prostate Cancer: The MEAL Randomized Clinical Trial. JAMA. 2020 Jan 14; 323 (2):140-148
    View PubMed
  37. Zahrieh D, Oleson JJ, Romitti PA. Quantifying geographic regions of excess stillbirth risk in the presence of spatial and spatio-temporal heterogeneity. Spat Spatiotemporal Epidemiol. 2019 Jun; 29:97-109 Epub 2019 Apr 09
    View PubMed
  38. Zahrieh D, Alexander A, Fruth B, Tan AD, Le-Rademacher J, Warsame R, Croghan K, Sloan JA. A Case Management System for Integrating Patient-reported Outcome Assessment in Clinical Practice: The Beacon Tool. Med Care. 2019 May; 57 Suppl 5 Suppl 1:S73-S79
    View PubMed
  39. Cathcart-Rake E, Smith D, Zahrieh D, Jatoi A, Yang P, Loprinzi CL. Nasal vestibulitis: an under-recognized and under-treated side effect of cancer treatment? Support Care Cancer. 2018 Nov; 26 (11):3909-3914 Epub 2018 May 24
    View PubMed
  40. Zahrieh D, Oleson JJ, Romitti PA. Bayesian point process modeling to quantify geographic regions of excess stillbirth risk Geographical Analysis. 2018.
  41. Van Horne S, Curran M, Smith A, VanBuren J, Zahrieh D, Larsen R, Miller R. Facilitating student success in introductory chemistry with feedback in an online platform Technology Knowledge And Learning. 2018 Apr; 23 (1):21-40
  42. Carrel M, Zahrieh D, Young SG, Oleson J, Ryckman KK, Wels B, Simmons DL, Saftlas A. High prevalence of elevated blood lead levels in both rural and urban Iowa newborns: Spatial patterns and area-level covariates. PLoS One. 2017; 12 (5):e0177930 Epub 2017 May 16
    View PubMed
  43. Elstein D, Haims AH, Zahrieh D, Cohn GM, Zimran A. Impact of velaglucerase alfa on bone marrow burden score in adult patients with type 1 Gaucher disease: 7-year follow-up. Blood Cells Mol Dis. 2014 Jun-Aug; 53 (1-2):56-60 Epub 2014 Feb 25
    View PubMed
  44. Pastores GM, Rosenbloom B, Weinreb N, Goker-Alpan O, Grabowski G, Cohn GM, Zahrieh D. A multicenter open-label treatment protocol (HGT-GCB-058) of velaglucerase alfa enzyme replacement therapy in patients with Gaucher disease type 1: safety and tolerability. Genet Med. 2014 May; 16 (5):359-66 Epub 2013 Nov 21
    View PubMed
  45. Morris JP 4th, Berghmans S, Zahrieh D, Neuberg DS, Kanki JP, Look AT. Zebrafish sperm cryopreservation with N, N-dimethylacetamide Biotechniques. 2013; 35(5):956-8, 960, 962 passim. Epub 2003 Jan 01.
  46. Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MF, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol. 2013 Mar; 88 (3):166-71 Epub 2013 Feb 06
    View PubMed
  47. Zimran A, Pastores GM, Tylki-Szymanska A, Hughes DA, Elstein D, Mardach R, Eng C, Smith L, Heisel-Kurth M, Charrow J, Harmatz P, Fernhoff P, Rhead W, Longo N, Giraldo P, Ruiz JA, Zahrieh D, Crombez E, Grabowski GA. Safety and efficacy of velaglucerase alfa in Gaucher disease type 1 patients previously treated with imiglucerase. Am J Hematol. 2013 Mar; 88 (3):172-8 Epub 2013 Jan 22
    View PubMed
  48. Elstein D, Foldes AJ, Zahrieh D, Cohn GM, Djordjevic M, Brutaru C, Zimran A. Significant and continuous improvement in bone mineral density among type 1 Gaucher disease patients treated with velaglucerase alfa: 69-month experience, including dose reduction. Blood Cells Mol Dis. 2011 Jun 15; 47 (1):56-61 Epub 2011 May 04
    View PubMed
  49. Gunnarsdottir KA, Jensen MB, Zahrieh D, Gelber RD, Knoop A, Bonetti M, Mouridsen H, Ejlertsen B. CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D. Breast Cancer Res Treat. 2010 Aug; 123 (1):163-9 Epub 2010 May 13
    View PubMed
  50. Yoon SO, Zhang X, Freedman AS, Zahrieh D, Lossos IS, Li L, Choi YS. Down-regulation of CD9 expression and its correlation to tumor progression in B lymphomas. Am J Pathol. 2010 Jul; 177 (1):377-86 Epub 2010 June 21
    View PubMed
  51. Bonetti M, Zahrieh D, Cole BF, Gelber RD. A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data. Stat Med. 2009 Apr 15; 28 (8):1255-68
    View PubMed
  52. Gorgun G, Ramsay AG, Holderried TA, Zahrieh D, Le Dieu R, Liu F, Quackenbush J, Croce CM, Gribben JG. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A. 2009 Apr 14; 106 (15):6250-5 Epub 2009 Mar 30
    View PubMed
  53. Kulke MH, Freed E, Chiang DY, Philips J, Zahrieh D, Glickman JN, Shivdasani RA. High-resolution analysis of genetic alterations in small bowel carcinoid tumors reveals areas of recurrent amplification and loss. Genes Chromosomes Cancer. 2008 Jul; 47 (7):591-603
    View PubMed
  54. Pestalozzi BC, Zahrieh D, Mallon E, Gusterson BA, Price KN, Gelber RD, Holmberg SB, Lindtner J, Snyder R, Thurlimann B, Murray E, Viale G, Castiglione-Gertsch M, Coates AS, Goldhirsch A, International Breast Cancer Study Group. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol. 2008 Jun 20; 26 (18):3006-14 Epub 2008 May 05
    View PubMed
  55. Wapnir IL, Aebi S, Geyer CE, Zahrieh D, Gelber RD, Anderson SJ, Robidoux A, Bernhard J, Maibach R, Castiglione-Gertsch M, Coates AS, Piccart MJ, Clemons MJ, Costantino JP, Wolmark N, IBCSG//BIG//NSABP. A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. Clin Breast Cancer. 2008 Jun; 8 (3):287-92
    View PubMed
  56. Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A. Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol. 2008 Mar; 19 (3):465-72 Epub 2007 Nov 06
    View PubMed
  57. Attar EC, De Angelo DJ, Supko JG, D'Amato F, Zahrieh D, Sirulnik A, Wadleigh M, Ballen KK, McAfee S, Miller KB, Levine J, Galinsky I, Trehu EG, Schenkein D, Neuberg D, Stone RM, Amrein PC. Phase I and pharmacokinetic study of bortezomib in combination with idarubicin and cytarabine in patients with acute myelogenous leukemia. Clin Cancer Res. 2008 Mar 1; 14 (5):1446-54
    View PubMed
  58. Saito AM, Cutler C, Zahrieh D, Soiffer RJ, Ho VT, Alyea EP, Koreth J, Antin JH, Lee SJ. Costs of allogeneic hematopoietic cell transplantation with high-dose regimens. Biol Blood Marrow Transplant. 2008 Feb; 14 (2):197-207
    View PubMed
  59. Bernhard J, Zahrieh D, Zhang JJ, Martinelli G, Basser R, Hurny C, Forbes JF, Aebi S, Yeo W, Thurlimann B, Green MD, Colleoni M, Gelber RD, Castiglione-Gertsch M, Price KN, Goldhirsch A, Coates AS, International Breast Cancer Study Group. Quality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer. Br J Cancer. 2008 Jan 15; 98 (1):25-33 Epub 2007 Nov 27
    View PubMed
  60. Saito AM, Zahrieh D, Cutler C, Ho VT, Antin JH, Soiffer RJ, Alyea EP, Lee SJ. Lower costs associated with hematopoietic cell transplantation using reduced intensity vs high-dose regimens for hematological malignancy. Bone Marrow Transplant. 2007 Aug; 40 (3):209-17 Epub 2007 June 11
    View PubMed
  61. Dileo P, Morgan JA, Zahrieh D, Desai J, Salesi JM, Harmon DC, Quigley MT, Polson K, Demetri GD, George S. Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial. Cancer. 2007 May 1; 109 (9):1863-9
    View PubMed
  62. Bernhard J, Zahrieh D, Castiglione-Gertsch M, Hurny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Thurlimann B, Price KN, Goldhirsch A, Coates AS, International Breast Cancer Study Group Trial VIII. Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients--the International Breast Cancer Study Group Trial VIII. J Clin Oncol. 2007 Jan 20; 25 (3):263-70 Epub 2006 Dec 11
    View PubMed
  63. Zirlik KM, Zahrieh D, Neuberg D, Gribben JG. Cytotoxic T cells generated against heteroclitic peptides kill primary tumor cells independent of the binding affinity of the native tumor antigen peptide. Blood. 2006 Dec 1; 108 (12):3865-70 Epub 2006 Aug 10
    View PubMed
  64. Pestalozzi BC, Zahrieh D, Price KN, Holmberg SB, Lindtner J, Collins J, Crivellari D, Fey MF, Murray E, Pagani O, Simoncini E, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A, International Breast Cancer Study Group (IBCSG). Identifying breast cancer patients at risk for Central Nervous System (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol. 2006 Jun; 17 (6):935-44 Epub 2006 Apr 07
    View PubMed
  65. Raut CP, Posner M, Desai J, Morgan JA, George S, Zahrieh D, Fletcher CD, Demetri GD, Bertagnolli MM. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol. 2006 May 20; 24 (15):2325-31
    View PubMed
  66. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, Gilliland DG, Busque L. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood. 2006 May 15; 107 (10):4139-41 Epub 2006 Jan 24
    View PubMed
  67. Rudenstam CM, Zahrieh D, Forbes JF, Crivellari D, Holmberg SB, Rey P, Dent D, Campbell I, Bernhard J, Price KN, Castiglione-Gertsch M, Goldhirsch A, Gelber RD, Coates AS, International Breast Cancer Study Group. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93. J Clin Oncol. 2006 Jan 20; 24 (3):337-44 Epub 2005 Dec 12
    View PubMed
  68. Gribben JG, Zahrieh D, Stephans K, Bartlett-Pandite L, Alyea EP, Fisher DC, Freedman AS, Mauch P, Schlossman R, Sequist LV, Soiffer RJ, Marshall B, Neuberg D, Ritz J, Nadler LM. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood. 2005 Dec 15; 106 (13):4389-96 Epub 2005 Aug 30
    View PubMed
  69. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005 Jul; 115 (7):1797-805 Epub 2005 June 16
    View PubMed
  70. Fraenkel PG, Traver D, Donovan A, Zahrieh D, Zon LI. Ferroportin1 is required for normal iron cycling in zebrafish. J Clin Invest. 2005 Jun; 115 (6):1532-41 Epub 2005 May 05
    View PubMed
  71. Mauerer K, Zahrieh D, Gorgun G, Li A, Zhou J, Ansen S, Rassenti LZ, Gribben JG. Immunoglobulin gene segment usage, location and immunogenicity in mutated and unmutated chronic lymphocytic leukaemia. Br J Haematol. 2005 May; 129 (4):499-510
    View PubMed
  72. Colleoni M, Zahrieh D, Gelber RD, Holmberg SB, Mattsson JE, Rudenstam CM, Lindtner J, Erzen D, Snyder R, Collins J, Fey MF, Thurlimann B, Crivellari D, Murray E, Mendiola C, Pagani O, Castiglione-Gertsch M, Coates AS, Price K, Goldhirsch A. Site of primary tumor has a prognostic role in operable breast cancer: the international breast cancer study group experience. J Clin Oncol. 2005 Mar 1; 23 (7):1390-400
    View PubMed
  73. Gricks CS, Zahrieh D, Zauls AJ, Gorgun G, Drandi D, Mauerer K, Neuberg D, Gribben JG. Differential regulation of gene expression following CD40 activation of leukemic compared to healthy B cells. Blood. 2004 Dec 15; 104 (13):4002-9 Epub 2004 May 25
    View PubMed
  74. Pagani O, Gelber S, Price K, Zahrieh D, Gelber R, Simoncini E, Castiglione-Gertsch M, Coates AS, Goldhirsch A, International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early-stage breast cancer: first results of International Breast Cancer Study Group Trials 12-93 and 14-93. Ann Oncol. 2004 Dec; 15 (12):1749-59
    View PubMed
  75. Bernhard J, Zahrieh D, Coates AS, Gelber RD, Castiglione-Gertsch M, Murray E, Forbes JF, Perey L, Collins J, Snyder R, Rudenstam CM, Crivellari D, Veronesi A, Thurlimann B, Fey MF, Price KN, Goldhirsch A, Hurny C. Quantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer. Br J Cancer. 2004 Nov 29; 91 (11):1893-901
    View PubMed
  76. Mutter GL, Zahrieh D, Liu C, Neuberg D, Finkelstein D, Baker HE, Warrington JA. Comparison of frozen and RNALater solid tissue storage methods for use in RNA expression microarrays. BMC Genomics. 2004 Nov 10; 5:88
    View PubMed
  77. Colleoni M, Viale G, Zahrieh D, Pruneri G, Gentilini O, Veronesi P, Gelber RD, Curigliano G, Torrisi R, Luini A, Intra M, Galimberti V, Renne G, Nole F, Peruzzotti G, Goldhirsch A. Chemotherapy is more effective in patients with breast cancer not expressing steroid hormone receptors: a study of preoperative treatment. Clin Cancer Res. 2004 Oct 1; 10 (19):6622-8
    View PubMed
  78. Lee SJ, Zahrieh D, Agura E, MacMillan ML, Maziarz RT, McCarthy PL Jr, Ho VT, Cutler C, Alyea EP, Antin JH, Soiffer RJ. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood. 2004 Sep 1; 104 (5):1559-64 Epub 2004 May 11
    View PubMed
  79. Ho VT, Zahrieh D, Hochberg E, Micale E, Levin J, Reynolds C, Steckel S, Cutler C, Fisher DC, Lee SJ, Alyea EP, Ritz J, Soiffer RJ, Antin JH. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood. 2004 Aug 15; 104 (4):1224-6 Epub 2004 Apr 27
    View PubMed
  80. Sekeres MA, Stone RM, Zahrieh D, Neuberg D, Morrison V, De Angelo DJ, Galinsky I, Lee SJ. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia. 2004 Apr; 18 (4):809-16
    View PubMed
  81. Zubair AC, Zahrieh D, Daley H, Schott D, Gribben JG, Alyea EP, Schlossman R, Freedman A, Antin JH, Soiffer RJ, Neuberg D, Ritz J. Engraftment of autologous and allogeneic marrow HPCs after myeloablative therapy. Transfusion. 2004 Feb; 44 (2):253-61
    View PubMed
  82. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Alyea EP, Antin JH, Stone RM, Soiffer RJ, DeAngelo DJ. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation Blood. 2003; 102(5):1578-82.
  83. Battle TE, Wierda WG, Rassenti LZ, Zahrieh D, Neuberg D, Kipps TJ, Frank DA. In vivo activation of signal transducer and activator of transcription 1 after CD154 gene therapy for chronic lymphocytic leukemia is associated with clinical and immunologic response Clin Cancer Res. 2003; 9(6):2166-72.
  84. Zubair A, Zahrieh D, Daley H, Schott D, Gribben JG, Freedman A, Ritz J. Early neutrophil engraftment following autologous BMT provides a functional predictor of long-term hematopoietic reconstitution. Transfusion. 2003 May; 43 (5):614-21
    View PubMed
  85. Colleoni M, Zahrieh D, Gelber RD, Viale G, Luini A, Veronesi P, Intra M, Galimberti V, Renne G, Goldhirsch A. Preoperative systematic treatment: prediction of responsiveness The Breast. 2003; 12(6):538-42.
  86. Lee SJ, Zahrieh D, Alyea EP, Weller E, Ho VT, Antin JH, Soiffer RJ. Comparison of T-cell-depleted and non-T-cell-depleted unrelated donor transplantation for hematologic diseases: clinical outcomes, quality of life, and costs Blood. 2002; 100(8):2697-702.
  87. International Breast Cancer Study Group, Zahrieh D. Endocrine responsiveness and tailoring adjuvant therapy for postmenopausal lymph node-negative breast cancer: a randomized trial J Natl Cancer Inst. 2002; 94(14):1054-65.
  88. Lin TS, Zahrieh D, Weller E, Alyea EP, Antin JH, Soiffer RJ. Risk factors for cytomegalovirus reactivation after CD6+ T-cell-depleted allogeneic bone marrow transplantation Transplantation. 2002; 74(1):49-54.
  89. Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion Biol Blood Marrow Transplant. 2002; 8(11):625-32.
  90. International Breast Cancer Study Group, Zahrieh D. Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine-responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93 The Breast. 2001; 10(3):130-138.